Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity

FEBS Open Bio

Volumn 6, Issue 1, 2016, Pages 64-76

  Chung, Hea Jong ^a   Yu, Jae G ^b   Lee, In Ah ^b   Liu, Ming Jie ^a   Shen, Yan Fei ^a   Sharma, Satya P ^a   Jamal, Mohammad A H M ^a   Yoo, Jun Hyun ^c   Kim, Hyeon Jin ^b   Hong, Seong Tshool ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Jinis Inc   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Lactobacillus; Absorption; Free fatty acid; Intestinal; Obesity

Indexed keywords

ACETIC ACID; ARACHIDONIC ACID; BEHENIC ACID; BUTYRIC ACID; CHOLESTEROL; FATTY ACID; HENEICOSANOIC ACID; HEPTANOIC ACID; HEXANOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAURIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYRISTIC ACID; NONADECANOIC ACID; OLEIC ACID; PALMITELAIDIC ACID; PALMITIC ACID; PENTADECANOIC ACID; PLACEBO; PROBIOTIC AGENT; PROPIONIC ACID; SEBACIC ACID; SHORT CHAIN FATTY ACID; STEARIC ACID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALEIC ACID; VALERIC ACID;

ABDOMINAL FAT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FAT INTAKE; FECES; FEMALE; HIGH THROUGHPUT SCREENING; HOST; HUMAN; INTESTINE ABSORPTION; INTESTINE FLORA; INTRAABDOMINAL FAT; LACTOBACILLUS; LACTOBACILLUS MUTANS; LACTOBACILLUS REUTERI; LIPID BLOOD LEVEL; LIPID STORAGE; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHYLOGENETIC TREE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SMALL INTESTINE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84957803320     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1002/2211-5463.12024     Document Type: Article

References (55)

1. Wells JC and Siervo M (2011) Obesity and energy balance: is the tail wagging the dog? Eur J Clin Nutr 65, 1173-1189.
2. Visscher TL and Seidell JC (2001) The public health impact of obesity. Annu Rev Public Health 22, 355-375.
3. Holes-Lewis KA, Malcolm R and O'Neil PM (2013) Pharmacotherapy of obesity: clinical treatments and considerations. Am J Med Sci 345, 284-288.
4. Kang JG and Park CY (2012) Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 36, 13-25.
5. Powell AG, Apovian CM and Aronne LJ (2011) New drug targets for the treatment of obesity. Clin Pharmacol Ther 90, 40-51.
6. Wright SM and Aronne LJ (2011) Obesity in 2010: the future of obesity medicine: where do we go from here? Nat Rev Endocrinol 7, 69-70.
7. Poirier P (2011) Weight loss drugs and cardiovascular risks. Curr Cardiovasc Risk Rep 5, 138-144.
8. James WPT, Caterson ID, Coutinho W, Finer N, Gaal LFV, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363, 905-917.
9. Yanovski SZ and Yanovski JA (2014) Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311, 74-86.
10. Guercolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21, S12-S23.
11. Hauptman JB, Jeunet FS and Hartmann D (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 55, 309S-313S.
12. Hill J, Hauptman J, Anderson J, Ken Fujioka K, O'Neil P, Smith D, Zavoral J and Aronne L (1999) Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 69, 1108-1116.
13. Jain R, Chung SM, Jain L, Khurana M, Lau SWJ, Lee JE, Vaidyanathan J, Zadezensky I, Choe S and Sahajwalla CG (2011) Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 90, 77-89.
14. Colman E, Golden J, Roberts M, Egan A, Weaver J and Rosebraugh C (2012) The FDA's assessment of two drugs for chronic weight management. N Engl J Med 367, 1577-1579.
15. Bays HE (2011) Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 9, 265-277.
16. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML and Day WW (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341-1352.
17. Halford JC, Boyland EJ, Blundell JE, Kirkham TC and Harrold JA (2010) Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 6, 255-269.
18. Dietrich MO and Horvath TL (2012) Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 11, 675-691.
19. Rueda-Clausen CF, Padwal RS and Sharma AM (2013) New pharmacological approaches for obesity management. Nat Rev Endocrinol 9, 467-478.
20. Ley RE, Turnbaugh PJ, Klein S and Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023.
21. Turnbaugh PJ, Bäckhed F, Fulton L and Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213-223.
22. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR et al. (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214.
23. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M and Tsuchida T (2010) Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 64, 636-643.
24. Le Barz M, Anhê FF, Varin TV, Desjardins Y, Levy E, Roy D and Marette A (2015) Probiotics as complementary treatment for metabolic disorders. Diabetes Metab J 39, 291-303.
25. Semova I, Carten JD, Stombaugh J, Mackey LC, Knight R, Farber SA and Rawls JF (2012) Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. Cell Host Microbe 12, 277-288.
26. Lin WH, Hwang CF, Chen LW and Tsen HY (2006) Viable counts, characteristic evaluation for commercial lactic acid bacteria products. Food Microbiol 23, 74-81.
27. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrné S and Bengmark S (1993) Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 59, 15-20.
28. Baek SH, Chung HJ, Lee HK, D'Souza R, Jeon Y, Kim HJ, Kweon SJ and Hong ST (2014) Treatment of obesity with the resveratrol-enriched rice DJ-526. Sci Rep 4, 3879.
29. Leenen R, van der Kooy K, Deurenberg P, Seidell JC, Weststrate JA, Schouten FJ and Hautvast JG (1992) Visceral fat accumulation in obese subjects: relation to energy expenditure and response to weight loss. Am J Physiol 263, E913-E919.
30. Keno Y, Matsuzawa Y, Tokunaga K, Fujioka S, Kawamoto T, Kobatake T and Tarui S (1991) High sucrose diet increases visceral fat accumulation in VMH-lesioned obese rats. Int J Obes 15, 205-211.
31. Després JP and Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444, 881-887.
32. Molavi B, Rasouli N and Kern PA (2006) The prevention and treatment of metabolic syndrome and high-risk obesity. Curr Opin Cardiol 21, 479-485.
33. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L and van der Veen EA (1995) Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 19, 221-226.
34. Rand CS (1987) Obesity and caloric intake. J Chronic Dis 40, 911-912.
35. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity: the Evidence Report. US Government Press, Washington, DC, USA.
36. Hill JO (2006) Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 27, 750-761.
37. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242.
38. Million M, Angelakisa E, Paulb M, Armougoma F, Leibovicic L and Raoulta D (2012) Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog 53, 100-108.
39. Fak F and Backhed F (2012) Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS One 7, e46837.
40. Qiao Y, Sun J, Xia S, Li L, Li Y, Wang P, Shi Y and Le G (2015) Effects of different Lactobacillus reuteri on inflammatory and fat storage in high-fat diet-induced obesity mice model. J Funct Foods 14, 424-434.
41. Ogawa A, Kadooka Y, Kato K, Shirouchi B and Sato M (2014) Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 13, 36.
42. Caesar R, Fåk F and Bäckhed F (2010) Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 268, 320-328.
43. Krajmalnik-Brown R, Ilhan ZE, Kang DW and DiBaise JK (2012) Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract 27, 201-214.
44. Collins SM and Bercik P (2009) The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003-2014.
45. Tilg H and Kaser A (2011) Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 121, 2126-2132.
46. Sekirov I, Russell SL, Antunes LC and Finlay BB (2010) Gut microbiota in health and disease. Physiol Rev 90, 859-904.
47. DiBaise JK, Frank DN and Mathur R (2012) Impact of the gut microbiota on the development of obesity: current concepts. Am J Gastroenterol Suppl 1, 22-27.
48. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D et al. (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60.
49. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER and Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031.
50. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett C, Knight R and Gordon JI (2007) The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 449, 804-810.
51. Bäckhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V and Finlay BB (2012) Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12, 611-620.
52. Clemente JC, Ursell LK, Parfrey LW and Knight R (2012) The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258-1270.
53. Delzenne NM, Neyrinck AM, Bäckhed F and Cani PD (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7, 639-646.
54. Musso G, Gambino R and Cassader M (2011) Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Ann Rev Med 62, 361-380.
55. Oliverio AM and Katz LA (2014) The dynamic nature of genomes across the tree of life. Genome Biol Evol 6, 482-488.